IVUS in Unprotected LMCA Angioplasty: Should We Change the Way We Use It?

Courtesy of Dr. Carlos Fava.

Bifurcation lesions account for about 25% of all angioplasties and it is a challenge for which there is no single treatment strategy.

La era del stent provisional para las bifurcaciones parece llegar a su fin

Intravascular ultrasound (IVUS) has proven its usefulness, improving outcomes by reducing mortality in unprotected left main coronary artery (LMCA) angioplasty.

A new strategy consists in conducting an IVUS after pre-dilation, after stent implantation, and post-dilation. However, such alternative has not been validated yet.

Researchers analyzed 9525 patients from the IRIS-DES registry with severe left main coronary artery, bifurcation, long or diffuse (>30 mm), or severely calcified lesions controlled through IVUS. Among them, 3374 (35.4%) patients underwent endoluminal ultrasound at pre-dilation, after stent implantation, and post-dilation (iPSP).


Read also: Detection of Late Complications After EVAR.


The primary endpoint at follow-up was cardiac death, target-vessel infarction, and target-vessel revascularization (TVR).

Patients who underwent iPSP angioplasty were younger and mostly male, had more risk factors, bifurcation lesions, severe calcification, longer lesions, and more stents. Consequently, researchers used propensity score matching to adjust populations and reach uniformity, leaving 3130 patients in each group.

The follow-up went on for 3 years and the primary endpoint favored iPSP patients (5.6% vs. 7.9%; adjusted hazard ratio [HR]: 0.71; 95% confidence interval [CI]: 0.63 to 0.81; p < 0.001).


Read also: EuroPCR 2020 | Aortic Valve in Valve in the Long Term.


Analyzing the secondary endpoints, iPSP was associated with lower mortality (2.2% vs. 3.4%; adjusted HR: 0.62; 95% CI: 0.51 to 0.75; p 0.003) and TVR (3.4% vs. 4.6%; adjusted HR: 0.74; 95% CI: 0.63 to 0.87; p < 0.001), and there were no differences as regards infarction (0.3% vs. 0.5%; adjusted HR: 0.65; 95% CI: 0.38 to 1.10; p = 0.10).

Conclusion

In patients who underwent complex unprotected left main coronary artery angioplasty with drug-eluting stents (DES), iPSP was associated with a lower risk of cardiac events after 3 years of follow-up.

Consequently, iPSP should be used more proactively in complex coronary angioplasties nowadays.

Courtesy of Dr. Carlos Fava.

Título Original: Optimal Stenting Technique for Complex Coronary Lesions Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation.

Referencia: Hanbit Park, el al. J AmColl Cardiol Intv 2020;13:1403–13.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...